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ABSTRACT
Introduction: Rituximab is increasingly used in
patients with pemphigus vulgaris (PV) who are
nonresponders to conventional therapy.
Methods: A PubMed search was conducted
using the words pemphigus vulgaris and
rituximab therapy from papers published
between 2000 and 2012. Two protocols were
used. In the lymphoma protocol, patients
received four weekly infusions of rituximab
(dose 375 mg/m2). The rheumatoid arthritis
(RA) protocol consisted of two infusions of
1,000 mg each 15 days apart. The variables
recorded from each study included clinical
remission off or on therapy, relapse rate,
incidence of serious adverse events,
concomitant therapies, duration of follow-up,
and when available, levels of B cells and
autoantibodies.
Results: Forty-two studies were found, which
reported 272 patients; 180 were treated by the
lymphoma protocol and 92 by the RA protocol.
Both protocols were effective in treating
recalcitrant PV. The lymphoma protocol had a
lower response rate, relapse rate and serious
infections, but higher mortality, and there were
nonresponders. The RA protocol produced a
higher response rate, relapse rate, number of
infections, but lower mortality rate, and lacked
nonresponders. The cumulative follow-up for
patients treated with the lymphoma protocol
was 15.44 months (range 1–41) and
21.04 months (range 8.35–29) for the RA
protocol. A major concern in both protocols
was the high infection rates, some of which
were fatal. A different protocol using a
combination of rituximab with intravenous
immunoglobulin in a defined manner with a
definitive endpoint, used in a limited cohort of
patients, showed promising results.
Conclusion: Neither protocol produced a
sustained clinical remission and both required
continued systemic therapy. Before initiation of
treatment, physicians should have a specific
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goal and endpoint and be aware of its potential
side effects and lack of information on its long-
term effects. Patients should be carefully
monitored during and after therapy.
Keywords: Clinical outcomes; Immunology
and inflammatory skin diseases; Lymphoma
protocol; Pemphigus vulgaris; Rheumatoid
arthritis protocol; Rituximab
INTRODUCTION
Pemphigus vulgaris (PV) is a potentially fatal
autoimmune mucocutaneous blistering disease
that involves the skin and the mucous
membranes [1]. PV is a rare disease with an
incidence of approximately 0.1–3.2 cases per
100,000 individuals annually worldwide [2]. It
is a disease of the middle-aged population,
typically occurring after the age of 50 years,
although some cases have been reported in
younger adults and children [3]. PV is seen more
frequently in people of Mediterranean decent
and Ashkenazi Jews [4]. The incidence in men
and women is equal [5].
The histology of PV is an intra-epidermal
vesicle with acantholysis [6]. The described
antigens are desmoglein 1 (Dsg 1) and
desmoglein 3 (Dsg 3) [7]. The immunopathology
demonstrates deposition of autoantibodies on
keratinocyte cell surfaces and their presence in
patients’ sera [8].
The mainstay of treatment of PV is systemic
corticosteroids. Immunosuppressive agents
(ISAs) are used for their steroid-sparing effect
and possible ability to reduce autoantibody
production [9–11]. Many patients do not
respond to high dose long-term corticosteroids
in combination with multiple ISAs. Newer
methods of treatment, such as rituximab, have
shown promise in such patients.
Rituximab is a chimeric monoclonal
antibody that targets the CD20 molecule on B
cells resulting in their lysis [12]. Pro-B cells,
plasmablasts, and plasma cells do not express
the CD20 molecule, and are unaffected by
rituximab [12]. In 1997, the US Food and Drug
Administration approved its use in lymphoma,
in 2006 for rheumatoid arthritis (RA), in 2010
for chronic lymphocytic leukemia, and in 2011
for Wegener’s granulomatosis [13]. Its use in PV
is off label [14]. The rationale for the use of
rituximab in patients with PV is based on
its ability to deplete CD20? B cells that
presumably produce pathogenic antibodies
[12].
The purpose of this review is to provide a
critical analysis of the use of rituximab in the
treatment of patients with PV.
METHODS
A PubMed search was conducted using the
following keywords: pemphigus vulgaris,
rituximab, anti-CD20 monoclonal antibody.
The patients included in this review were
derived from studies published between 2000
and the present.
The following inclusion criteria were used: (1)
English language; (2) clinical profile consistent
with PV; (3) routine histology demonstrating
suprabasilar cleft with acantholysis; (4)
demonstration of intra-epidermal deposition of
immunoreactants on perilesional skin processed
by direct immunofluorescence; (5) whenever
possible, information on treatments used
concomitantly as well as after rituximab
therapy; (6) information on dose and frequency
of rituximab therapy; (7) provision of clinical
outcomes at the end of the study period; (8)
occurrence of relapses if they occur, and
management of the relapse; (9) reporting the
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length of follow-up; (10) documentation of
serious adverse events, especially infections and
mortality or lack thereof.
The information retrieved was categorized as
follows: patient number, dose of rituximab and
number of cycles, concomitant therapies,
follow-up duration, adverse effects, clinical
outcomes, relapses with re-treatments, levels
of B cells, and autoantibody levels. The data are
divided into case reports and case series. Case
series included a minimum of six patients.
The patients were treated according to the
lymphoma or RA protocol with rituximab. The
lymphoma protocol consists of four weekly
infusions of 375 mg/m2 [14]. The RA protocol
consists of two infusions of 1,000 mg 2 weeks
apart [14].
Clinical outcomes of rituximab therapy
included were used as described by Murrell
et al. [15]. Complete remission on or off therapy
was recorded as reported. In this analysis, partial
responders were those patients in whom,
after the initiation of rituximab therapy,
the dose of systemic corticosteroids and
immunosuppressive agents could be reduced
by less than 50% compared to the prerituximab
dose. Furthermore, in those patients, clinical
disease occurred at intermittent periods, but
did not require additional systemic therapy.
Nonresponders were those patients who showed
no clinical improvement and were considered
treatment failures.
RESULTS
In 42 different publications, information on a
total of 272 individual patients with PV treated
with rituximab between 2000 and 2012 was
available [16–57]. These data were divided into
patients treated by (1) the lymphoma protocol,
(2) the RA protocol, and (3) modifications or
different combinations of either protocol. The
information in each of the protocols was
divided into case reports and case series.
In the lymphoma protocol, 22 case reports
described 48 patients [16–37] and seven case
series described 88 patients [43–49]. There are
thus 136 patients who were treated by the
lymphoma protocol.
There were no case reports in the RA
protocol. Four case series described 75 patients
[50–53].
Varying and modified versions of the RA or
the lymphoma protocols were used within the
same group of patients. Ten patients in five case
reports got modified versions of the lymphoma
protocol [38–42]. There were 51 patients in four
different case series [54–57]. Therefore, when
the case series and case reports are grouped
together, 61 patients received the modified
protocols.
The data on these different categories have
been summarized in Table 1.
The Lymphoma Protocol
Case Reports
The clinical outcomes were as follows [16–37]:
complete remission was observed in 32
(66.67%) patients; nine (18.75%) off therapy;
21 (43.75%) on therapy; and two (4.17%)
with unclear treatment status. Nine (18.75%)
were partial responders. Seven (14.58%) were
nonresponders, one of whom after a second
cycle had a complete response. The mean
duration of follow-up was 12.91 months (range
1–36 months).
Concomitant therapies included: 10
(20.83%) patients on systemic corticosteroids
alone [18, 20, 23, 30, 35, 36]; 36 (75%) patients
on corticosteroids and ISAs [16, 17, 19, 21, 22,
24–26, 28, 29, 31–34, 37]. Two (4.17%) patients
received rituximab as monotherapy [27].
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Six (12.5%) patients had seven relapses
after a mean time of 8.73 months (range
1.5–12 months) after discontinuing rituximab
[16, 22, 30, 31, 33]. One patient relapsed twice
and received an infusion of rituximab each
time. One patient received ISAs, while the
remaining four patients received a second
cycle of rituximab.
Serious adverse events reported included one
death from Pneumocystis carinii pneumonia
4 months after rituximab [21], one death from
septic shock after 16 months [36], one sepsis with
multidrug-resistant Pseudomonas aeruginosa,
Enterococcus faecalis, and Staphylococcus aureus
[16], one bacterial pneumonia [22], one
recurrence of P. aeruginosa hip arthritis [22], one
severe late-onset neutropenia after 27 weeks
[28], one late-onset neutropenia and bacterial
pneumonia after 19 weeks [29], one
cytomegalovirus gastritis and retinitis [29], one
deep vein thrombosis and pulmonary embolism
[33], and one P. carinii pneumonia [33].
The time to depletion of B cells
(undetectable levels in peripheral blood) after
the first rituximab infusion was available for 31
(64.58%) patients and varied from 1 week to
7 months (mean 1.76 months) [16, 17, 20,
22–24, 26, 27, 29–31, 33, 35]. The mean
duration of depletion of B cells was available
for 18 (37.5%) patients and was 12.84 months
(range 2–23.6 months) [16, 17, 20, 22, 24, 26,
27, 29, 33]. The mean time for repopulation of B
cells (return to levels present in the peripheral
blood before rituximab therapy) was available
for 15 (31.25%) patients and was 12.43 months
(range 5.5–23.6 months) [20, 22, 24, 26, 30, 31,
33].
Of the 15 (31.25%) patients reported with
indirect immunofluorescence (IIF) only,
two patients’ titers remained unchanged
throughout the study period, one of whom
had two relapses [16, 17]. Two patients had an
increase in their titers, one of whom relapsed as
the titers increased while the other relapsed
5 months earlier than the increase [22]. Eleven
patients had a decrease in titers at the end of the
study period with no relapses reported [21–23,
29, 34]. In the 20 (41.67%) patients in whom
enzyme-linked immunosorbent assay (ELISA)
for Dsg 1 and Dsg 3 were performed, decreases
in titers were observed with rituximab therapy
and clinical response [26, 30, 31, 33, 35, 37]. A
similar pattern was observed in 10 (20.83%)
patients in whom both IIF and ELISA data were
available [18, 20, 24, 25, 27, 32].
Case Series
Data on 88 patients were reported in seven case
series [43–49]. Clinical response was as follows:
complete response was observed in 56 (63.63%)
patients; seven (8%) patients were off therapies;
34 (38.63%) patients were on therapy; and 15
(17%) patients had an unclear therapy status.
Six (6.82%) patients had partial remission.
Twenty-six (29.55%) patients improved
but the definition of improvement was
undefined. Nonresponders were not reported.
The mean follow-up was 21.75 months (range
10.8–41 months).
Twenty-seven (30.68%) patients relapsed 29
times after a mean of 17.85 months (range
6–34 months) after discontinuation of
rituximab [43, 45–49]. Nine of these patients
were re-treated with additional rituximab
cycles. Three patients were treated with two
rituximab infusions 1,000 mg each, 3 weeks
apart. Four patients received low-dose
prednisone.
Serious adverse events included one death
from septicemia after 18 months [43], and one
pyelonephritis 12 months after discontinuation
of rituximab [43].
Depletion of B cells was reported in 35
patients and occurred between 1 and 4 weeks,
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and lasted up to 12 months [43–45]. Time for B
cell repopulation occurred between 12 and
34 months (mean 18.93 months). The data
suggest that the probability of relapse is higher
in patients who take longer to repopulate.
In the majority of patients, a decrease in Dsg
3 titers was reported [43–49]. Nonetheless, 11
(12.5%) patients had persistently high titers
while in clinical remission [43, 49]. Also, six
patients who experienced a relapse at 12 and
18 months had increased titers at the time of
relapse [48]. In 28 (31.8%) patients rituximab
therapy resulted in a decrease in Dsg 1 antibody
titers [43, 44, 47].
The Rheumatoid Arthritis Protocol
Case Series
Data on 75 patients were reported in four
studies [50–53]. Complete remission was
reported in 59 (78.67%) patients, of whom 44
(58.67%) were off therapy, 11 (14.67%) on
therapy, and in four patients (5.33%) the
therapy was unclear. Fifteen (20%) patients
had partial remission, and one (1.33%) patient
died. The mean duration of follow-up was
18.66 months (range 8.35–29 months).
Twenty-eight (37.33%) patients had 43
relapses [51–53]. Nine patients had two
relapses. Three patients relapsed three times
[53]. Relapses were treated with rituximab with
success. In some patients, corticosteroids, ISAs,
and immunoadsorption were used.
Adverse events occurred in 15 patients (20%)
[50–53]. These included one death from sepsis
with S. aureus [50]. Two other patients had
sepsis [50, 51], one of whom had spinal
hemorrhage with transient paraplegia of both
legs, three had pneumonias [52, 53], six urinary
tract infections [53], one extensive herpes
simplex infection [51], one herpes keratitis
[53], and one herpes zoster [53].
B cell levels were depleted within 1–4 weeks
[51–53]. Approximately 80% of these were
complete responders and 20% were partial
responders.
IIF decreased in two patients studied [52]. In
one patient, a relapse was accompanied by a rise
in the titer [52]. ELISA levels decreased in some
patients [50, 51, 53].
Modified Protocols
Case Reports
In ten patients, the modified lymphoma
protocol was used [38–42]. Patients receiving
modified lymphoma protocols received three or
four additional monthly infusions and one
received a complete second cycle of the
protocol. Eight (80%) patients had complete
remission, two (20%) had partial remission.
None of the patients had relapses. Patients
received corticosteroids or corticosteroids and
ISAs as concomitant therapies. One patient
experienced a bacterial pneumonia and
pulmonary embolism [39].
B cell studies were not reported and antibody
titers determined by IIF and ELISA decreased
[38, 39, 41].
One study reported three patients treated
with rituximab without details of the protocol
[58]. They were not included in the analysis.
Case Series
Data on 51 patients were presented in four
studies [54–57]. In the first study, six patients
received eight weekly infusions of 375 mg/m2
followed by a single dose once a month for
4 months [55]. All six had a complete remission
off therapy. In 25 patients, two separate
protocols were used [56]. One group received
375 mg/m2 in two infusions in 2 weeks. Half of
the patients had a complete remission and the
other half had a partial remission. In the second
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group, patients got three or more weekly
infusions of 375 mg/m2, and 90% had
complete remission while 10% had partial
remission. In the third study, 12 patients
received the RA protocol at a dose of 500 mg
at 2 week intervals [54]. Six of the 12 had
complete remission off and on therapy, and
six had partial remission. The fourth study
concerned eight patients [57]. Of the four
patients who got the RA protocol at a dose of
1,000 mg at 2 weeks, two had complete
remission and two had partial remission. One
patient received two infusions of 500 mg at
2 week intervals and had a complete remission.
The remaining three patients received the
lymphoma protocol, two had complete
remission and one had a partial remission.
Among the 51 patients in the modified
protocol group, 18 (35.3%) patients had
relapses after a mean of 18.75 months (range
11.5–24.25 months) [54, 56, 57]. Half were
treated with a second cycle of rituximab and
experienced a complete remission [54, 57].
Serious adverse events were reported in three
(5.8%) patients [54, 56]. One had gastric
perforation resulting in death [56], one had
cardiac complications [54], and one had sepsis
with neutropenia 7.25 months later [54].
Depletion of B cells lasted up to 40 months
in studies that reported it [54, 55]. In seven
patients, repopulation was observed after
20–35 months. In five (71%) of these patients,
repopulation was accompanied by relapses.
None of the studies reported IIF. ELISA for
both Dsg 1 and Dsg 3 reported decreases [56,
57].
DISCUSSION
The analysis of the available literature on the
use of rituximab in treating patients with PV is
not only difficult but restrictive, as a direct
consequence of the significant limitations of
the data. Therefore, interpretation of the data
analysis must be done in the light and
perspective of these limitations. An obvious
inference would be that such an analysis could
be of limited value. On the contrary, these
limitations are of significant benefit, because
they will help in the design of future
studies, and focus on elements of the
pharmacodynamics of rituximab therapy.
Some of these limitations are as follows: the
data come from multiple sources; there is a
significant lack of uniformity in the selection of
the patients, in defining their severity or extent
of disease, and in identifying failed treatment
before rituximab; the lack of an objective
scoring system makes changes or responses
difficult to evaluate numerically; the more
concerning aspect is the limited follow-up
provided by most authors, this becomes an
important issue because significant side effects
and relapses can occur several months after the
discontinuation of rituximab therapy.
As rituximab is a B cell depletion therapy,
many authors have not provided any data on B
cell levels and the changes in autoantibody
levels. None of the studies provide any rationale
or scientific basis for the use of the lymphoma
or RA protocols in treating patients with PV.
The response ofpatients to rituximab using the
lymphoma protocol or RA protocol has been
described in the results section. The total
number of patients treated by the lymphoma
protocol and its modification was 180. Ninety-
two patients were treated with the RA protocol
including its modifications. The length of follow-
up for patients in the lymphoma protocol was a
mean of 15.44 months (range 1–41 months) and
21.04 months (range 8.35–29 months) for the
RA protocol. These figures permit preliminary
conclusions. A complete remission occurred in
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66.66% of patients on the lymphoma protocol
and 75% in the RA protocol. This would suggest
that both protocols are effective in producing
clinical remissions during an 18-month follow-
up. Using the lymphoma protocol during this
period, 11.11% of these patients are off therapy
and 33.33% are on therapy. In contrast, in the RA
protocol, 53.26% are off therapy and 17.4% are on
therapy. This apparent difference is partly due to
the fact that the number of patients in whom the
presence or absence of therapy while in complete
remission is not mentioned in 22.22% of the
patients in the lymphoma protocol, but only in
4.34% of the patients in the RA protocol.
Interestingly, a partial response was observed in
12.78%ofpatients in the lymphomaprotocol, but
23.91% of the patients in the RA protocol. Of
significant interest is the fact that there were no
nonresponders in patients treated with the RA
protocol compared to 3.9% in the lymphoma
protocol. The relapse rates were 22.78% in the
lymphoma protocol and 35.87% in the RA
protocol. The incidence of serious infections was
3.9% in the lymphoma protocol but 15.21% in
the RA protocol. The mortality rate in the
lymphoma protocol was 2.22% and 1.09% in the
RA protocol. The difference between the two
protocols in these important variables is striking
and noteworthy. It is thus clear that there are
significant and remarkable differences in the
patient responses between the two protocols.
The data analysis did not provide clear
indications for specific reasons that may account
for these differences.
Preliminary observations would suggest that
while the use of the lymphoma protocol
produces a lower response rate, there is a
lower rate of recurrences and serious infections
but a higher mortality rate. Patients treated by
the RA protocol had higher response rates, a
larger number of infections, but a lower
mortality rate. This could be partly due to the
fact that more patients were on corticosteroids
and immunosuppressive agents as concomitant
therapy in the lymphoma protocol, thus adding
to the degree and duration of prolonged
immune suppression.
To serve the best interests of the patient, it is
useful and relevant to determine what purpose
the lymphoma and RA protocols serve in their
respective diseases. The use of rituximab
in lymphoma patients has a duration of
response of a median of 12 months (range
11–13.4 months) after which relapses frequently
occur [59]. A median progression-free survival of
18 months and a 5-year relapse free survival of
28% was reported [59]. The most relevant use of
rituximab comes from a 3-year progression-free
survival study in which patients were given
cyclophosphamide, doxorubicin, vincristine,
and prednisone-like chemotherapy with or
without rituximab and the 3-year survival rates
were 93% and 84%, respectively [60]. Therefore,
to obtain the benefit of rituximab in lymphoma
patients, the addition of other chemotherapeutic
agents is required, and can be best measured in
3-year survival rates.
The use of rituximab in RA is still a matter of
debate and discussion. Between 2006 and 2011,
5,903 patients, who were reported in eight
different trials, were treated [61–68]. These
studies compared various parameters. The
benefits of rituximab are measured by the
American College of Rheumatology’s 20%, 50%
and 70% improvement criteria [61–68]. The only
statistically significant dose regime was two cycles
of 1,000 mg of rituximab over 48 weeks that
achieved an American College of Rheumatology
improvement of 20%. The Rituximab Consensus
Expert Committee in 2011 stated that the optimal
treatment paradigms have not yet been defined
[69]. Recently, two extremely different treatment
options have been suggested. In the treatment to
target protocol, rituximab is given to keep the
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disease activity score at 2.6 or less whether
clinically needed or not. In the other protocol,
rituximab is given on an as-needed basis [70].
Some patients need five cycles or more to
maintain clinical remission [71–73]. However, at
the present time, there is no protocol that
provides prolonged and sustained remission in
RA. Therefore, it is unclear how many cycles are
required to keep patients symptom free, prevent
joint destruction, or can be safely given in any
defined period. Furthermore, RA patients usually
receive rituximab with methotrexate
concomitantly and often additional prednisone
[61–68]. PV treated by the RA protocol needed
multiple infusions to treat recurrent relapses [52,
53].
The objectives of treating patients with PV
are different from those with lymphoma or RA.
The optimal treatment for PV is one in which
the disease is controlled, relapses are prevented,
and the long-term sustained clinical remission
without continued treatment can be achieved.
In patients with PV and ocular cicatricial
pemphigoid, a defined protocol with a definitive
endpoint was used [74, 75]. This combination of
rituximab and intravenous immunoglobulin
allowed for the discontinuation of previous
systemic corticosteroids and ISAs and produced
sustained clinical remissions. There were no
infections or deaths.
There is a growing trend among
dermatologists to use rituximab. Many variables
have yet to be determined or defined. Providing
guidelines or indications for therapy is
preliminary and may change in the future.
Presently, the indications for using rituximab
could be as follows.
• Failure of conventional therapy for
minimally 6 months.
• When conventional therapy has failed,
or produced significant and catastrophic
side effects, or is contraindicated, then
intravenous immunoglobulin may be used
[76].
• Active or latent infections are a definitive
contraindication.
• Before initiating rituximab therapy, the goals
and the endpoint should be discussed. The
long-term side effects of rituximab in patients
with PV are not yet known. Rituximab can
result in cardiac side effects [77, 78]. Patients
and their families should be advised of these
facts.
• As clinical response may be faster with
rituximab compared to conventional
therapy, patients should be advised to return
at frequent intervals for the early detection of
possible recurrences and also for monitoring
of late-onset side effects.
CONCLUSION
The use of rituximab in PV is an evolving work
in progress. Although the data have limitations,
the drug is effective in controlling recalcitrant
disease. Whether this control is long term, life
long, or of limited duration is not yet known.
The data suggest that following either the
lymphoma or RA protocols is not optimal or
particularly advantageous, and modifications of
both are warranted. Both carry a risk of severe
and possibly fatal infections. Presently, it should
be the treatment of last resort. Monitoring the
levels of B cells (CD19?/CD20?) in the
peripheral blood and immunoglobulin levels
during and after therapy is advisable. A protocol
that is unique for autoimmune mucocutaneous
blistering disease is needed. Preliminary studies
using such a protocol show promising results
[74, 75]. Rituximab is the new frontier for the
treatment of PV.
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